ファイル | |
言語 |
英語
|
著者 |
Okimoto, Tamio
Division of Medical Oncology & Respiratory Medicine, Department of Internal Medicine, Shimane University, Japan
|
内容記述(抄録等) | A 40-year-old Japanese man with advanced pulmonary adenocarcinoma harboring anaplastic lymphoma kinase (ALK)-rearranged was administered the selective ALK inhibitor ceritinib as a third-line treatment and continued treatment for nine months. After fourth-line treatment, we performed rechallenge with ceritinib as a fifth-line treatment. On day 54 after rechallenge, the patient developed acutely deteriorating dyspnea. Chest computed tomography showed extensive ground-glass opacities. We diagnosed him with ceritinib-induced interstitial lung disease (ILD) and initiated methylprednisolone pulse therapy. To our knowledge, this is the first report of ceritinib-induced ILD in a Japanese patient. Since it may newly emerge with rechallenge therapy, close attention is necessary.
|
主題 | ceritinib
interstitial lung disease
anaplastic lymphoma kinase
adverse event
|
掲載誌名 |
Internal medicine
|
巻 | 59
|
号 | 2
|
開始ページ | 253
|
終了ページ | 256
|
ISSN | 0918-2918
|
ISSN(Online) | 1349-7235
|
発行日 | 2019
|
DOI | |
出版者 | 一般社団法人 日本内科学会
|
出版者ヨミ | イッパン シャダンホウジン ニホン ナイカ ガッカイ
|
出版者別表記 | The Japanese Society of Internal Medicine
|
資料タイプ |
学術雑誌論文
|
ファイル形式 |
PDF
|
著者版/出版社版 |
著者版
|
業績ID | e38014
|
部局 |
医学部
|